Drug Type Induced pluripotent stem cells (iPSC) |
Synonyms |
Target |
Action inhibitors |
Mechanism ROR2 inhibitors(Tyrosine-protein kinase transmembrane receptor ROR2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Neoplasms | Preclinical | United States | 13 Feb 2023 | |
| Sarcoma | Preclinical | United States | 13 Feb 2023 |





